Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Sponsor:FLX Bio, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS7290
U.S. Government ID:NCT03674567
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This study is designed to test different doses of FLX475 to see if it is safe and to study how the drug is absorbed and how the human body gets rid of the drug. The study will test FLX475 alone and in combination with pembrolizumab, a drug already approved by the United States Food and Drug Administration (FDA) for the treatment of patients with certain types of cancers. Pembrolizumab also works to stimulate your immune system and is also known as a checkpoint inhibitor. The objective of the study is to assess the safety and activity of FLX475 alone and FLX475 in combination with pembrolizumab at different dosages in patients with different cancers.

Do You Qualify?
Are you 18 years of age or older?YesNo
Have you been diagnosed with a metastatic tumor that has progressed after treatment with other therapies?YesNo
Are you able to swallow tablets without difficulty?YesNo
Submit
Cancel
Investigator
Jennifer Amengual, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162